317 related articles for article (PubMed ID: 26372487)
1. Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia.
Kapoor SW; Magambo KA; Kalluvya SE; Fitzgerald DW; Peck RN; Downs JA
AIDS; 2015 Nov; 29(18):2473-8. PubMed ID: 26372487
[TBL] [Abstract][Full Text] [Related]
2. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
Meya DB; Kiragga AN; Nalintya E; Morawski BM; Rajasingham R; Park BJ; Mubiru A; Kaplan JE; Manabe YC; Boulware DR
J Acquir Immune Defic Syndr; 2019 Feb; 80(2):182-189. PubMed ID: 30399034
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
Lakoh S; Rickman H; Sesay M; Kenneh S; Burke R; Baldeh M; Jiba DF; Tejan YS; Boyle S; Koroma C; Deen GF; Beynon F
BMC Infect Dis; 2020 Feb; 20(1):141. PubMed ID: 32059703
[TBL] [Abstract][Full Text] [Related]
4. A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda.
Nalintya E; Meya DB; Lofgren S; Huppler Hullsiek K; Boulware DR; Rajasingham R
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):231-238. PubMed ID: 29509588
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
[TBL] [Abstract][Full Text] [Related]
6. Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.
Faini D; Kalinjuma AV; Katende A; Mbwaji G; Mnzava D; Nyuri A; Glass TR; Furrer H; Hatz C; Boulware DR; Letang E
J Acquir Immune Defic Syndr; 2019 Feb; 80(2):205-213. PubMed ID: 30422904
[TBL] [Abstract][Full Text] [Related]
7. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.
Parkes-Ratanshi R; Wakeham K; Levin J; Namusoke D; Whitworth J; Coutinho A; Mugisha NK; Grosskurth H; Kamali A; Lalloo DG;
Lancet Infect Dis; 2011 Dec; 11(12):933-41. PubMed ID: 21982529
[TBL] [Abstract][Full Text] [Related]
8. Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm
Wykowski J; Galagan SR; Govere S; Wallis CL; Moosa MY; Celum C; Drain PK
BMC Infect Dis; 2020 Jan; 20(1):61. PubMed ID: 31959112
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa.
Govender NP; Roy M; Mendes JF; Zulu TG; Chiller TM; Karstaedt AS
HIV Med; 2015 Sep; 16(8):468-76. PubMed ID: 25689352
[TBL] [Abstract][Full Text] [Related]
10. Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts.
Montgomery MP; Nakasujja N; Morawski BM; Rajasingham R; Rhein J; Nalintya E; Williams DA; Huppler Hullsiek K; Kiragga A; Rolfes MA; Donahue Carlson R; Bahr NC; Birkenkamp KE; Manabe YC; Bohjanen PR; Kaplan JE; Kambugu A; Meya DB; Boulware DR;
BMC Neurol; 2017 Jun; 17(1):110. PubMed ID: 28606065
[TBL] [Abstract][Full Text] [Related]
11. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.
Liechty CA; Solberg P; Were W; Ekwaru JP; Ransom RL; Weidle PJ; Downing R; Coutinho A; Mermin J
Trop Med Int Health; 2007 Aug; 12(8):929-35. PubMed ID: 17697087
[TBL] [Abstract][Full Text] [Related]
12. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.
Rugemalila J; Maro VP; Kapanda G; Ndaro AJ; Jarvis JN
Trop Med Int Health; 2013 Sep; 18(9):1075-1079. PubMed ID: 23937699
[TBL] [Abstract][Full Text] [Related]
13. Laboratory Reflex and Clinic-Based Point-of-Care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality Among People Living With HIV.
Drain PK; Galagan SR; Govere S; Krows M; Thulare H; Wallis CL; Gosnell BI; Moosa MY; Celum C; Bassett IV
J Acquir Immune Defic Syndr; 2021 Aug; 87(5):1205-1213. PubMed ID: 33990495
[TBL] [Abstract][Full Text] [Related]
14. Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia.
Pac L; Horwitz MM; Namutebi AM; Auerbach BJ; Semeere A; Namulema T; Schwarz M; Bbosa R; Muruta A; Meya DB; Manabe YC
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):e69-76. PubMed ID: 25761234
[TBL] [Abstract][Full Text] [Related]
15. Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality.
Letang E; Müller MC; Ntamatungiro AJ; Kimera N; Faini D; Furrer H; Battegay M; Tanner M; Hatz C; Boulware DR; Glass TR
Open Forum Infect Dis; 2015 Apr; 2(2):ofv046. PubMed ID: 26213690
[TBL] [Abstract][Full Text] [Related]
16. No association of cryptococcal antigenemia with poor outcomes among antiretroviral therapy-experienced HIV-infected patients in Addis Ababa, Ethiopia.
Smitson CC; Tenna A; Tsegaye M; Alemu AS; Fekade D; Aseffa A; Blumberg HM; Kempker RR
PLoS One; 2014; 9(1):e85698. PubMed ID: 24465651
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the initial 12 months of a routine cryptococcal antigen screening program in reduction of HIV-associated cryptococcal meningitis in Uganda.
Enock K; Julius K; Griffith BC; Abila DB; Rutakingirwa MK; Kasibante J; Kandole KT; Kwizera R; Semeere A; Meya DB
BMC Health Serv Res; 2022 Mar; 22(1):301. PubMed ID: 35246128
[TBL] [Abstract][Full Text] [Related]
18. Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study.
Wajanga BM; Kalluvya S; Downs JA; Johnson WD; Fitzgerald DW; Peck RN
J Int AIDS Soc; 2011 Oct; 14():48. PubMed ID: 21988905
[TBL] [Abstract][Full Text] [Related]
19. Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program.
Wake RM; Govender NP; Omar T; Nel C; Mazanderani AH; Karat AS; Ismail NA; Tiemessen CT; Jarvis JN; Harrison TS
Clin Infect Dis; 2020 Apr; 70(8):1683-1690. PubMed ID: 31179488
[TBL] [Abstract][Full Text] [Related]
20. Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program.
Beyene T; Zewde AG; Balcha A; Hirpo B; Yitbarik T; Gebissa T; Rajasingham R; Boulware DR
Clin Infect Dis; 2017 Nov; 65(12):2126-2129. PubMed ID: 29020172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
